Wenyue Hu

Wenyue Hu

Auto-generated profile, based on publicly available information

Wenyue Hu

Vividion Therapeutics, San Diego, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2025 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
MBMario Beilmann
Mario Beilmann
KAKarissa Adkins
Karissa Adkins
HBHarrie C. M. Boonen
Harrie C. M. Boonen
PHPhilip Hewitt
Philip Hewitt
WHWenyue Hu
Wenyue Hu
TVTerry van Vleet
Terry van Vleet

1 November 2021 in Microbiological Research
Verified
Journal Article
Closed access
WHWenyue Hu
Wenyue Hu
YWYuli Wang
Yuli Wang
BYBingxu Yang
Bingxu Yang
LCLin Chen
Lin Chen
HYHao Yu
Hao Yu
XHXinyi He
Xinyi He

25 July 2024 in Toxicologic Pathology
Verified
Journal Article
Closed access
WHWenyue Hu
Wenyue Hu
BBBernard S. Buetow
Bernard S. Buetow
KSKaruna Sachdeva
Karuna Sachdeva
MLMichael W. Leach
Michael W. Leach
The toxicity of ATR-107, a human anti-interleukin-21 receptor (IL-21R) monoclonal antibody (mAb), was evaluated in CD-1 mice and cynomolgus monkeys after single-dose intravenous (IV) administration, and in Sprague-Dawley (SD) rats and cynomolgus monkeys after weekly IV and subcutaneous (SC) administration in 13-week toxicity studies that included recovery. Adverse liver necrosis, diffuse bridging fibrosis, and higher liver enzymes occurred in rats in the low-dose IV group (10 mg/kg), but not at 50 or 250 mg/kg IV, and not following SC administration despite overlapping systemic ATR-107 exposures. Similar findings were not seen in mice or cynomolgus monkeys. A series of investigative rat toxicity studies showed liver findings only occurred after administration of at least 3 weekly doses, only occurred in rats that developed anti-drug antibodies (ADAs), and the incidence was associated with higher ADAs titers. However, the presence of ADAs did not always result in liver injury. Liver findings did not occur in nude rats, which had high ATR-107 exposures and no ADAs. These findings suggest an adaptive immune response with formation of ADAs was necessary for development of ATR-107-related liver findings, and that liver injury can occur in rats secondary to development of ADAs following repeated administration of a human therapeutic mAb.